DDInter119 DDInter1026
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.
Larotrectinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Larotrectinib {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Larotrectinib may lead to a major life threatening interaction when taken with Pimozide